• Mitral Valve Regurgitation Quantification From 3D Color Doppler Ultrasound - Standard of Care Data Collection

  NCT03286088

  CompletedInterventionalNot ApplicableUpdated Oct 27, 2021
• Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant Volume

  NCT07528781

  RecruitingObservationalUpdated Apr 14, 2026
• New Techniques to Evaluate Mitral Regurgitation

  NCT01063322

  CompletedObservationalUpdated Dec 17, 2019
• Imaging by 4 DFlow in Patients With Tetralogy of Fallot

  NCT03542968

  Unknown statusInterventionalNot ApplicableUpdated Jan 23, 2020
• 4D Velocity Mapping of the Heart in rTOF Patients

  NCT02980614

  CompletedInterventionalNot ApplicableUpdated Jun 25, 2026
• 3D Ultrasound Myocardial Mechanical Wave Measurements

  NCT06648577

  RecruitingObservationalUpdated Nov 18, 2025

ClinicalTrials.gov ID

NCT07066904

Lead Sponsor

Assistance Publique - Hôpitaux de ParisOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

160Estimated

Last Update Posted

Jul 15, 2025Actual

Start Date

Oct 1, 2025Estimated

Primary Completion Date

Apr 30, 2028Estimated

Completion Date

Apr 30, 2028Estimated

Official Title

Quantification of Mitral Regurgitation Using 4D MRI Flow : Comparison With 2D MRI Flow and Echocardiography Using the Evolution of Left Ventricular Remodeling as a Reference

Brief Summary

The goal of this study is to evaluate whether 4D MRI provides a better assessment of mitral regurgitation quantification and associated ventricular remodeling than standard imaging techniques: echocardiography and 2D MRI, in patients suffuring from mitral regurgitation. 4D MRI demonstrated its superiority to 2D MRI in some other valve diseases but remains not widely used, due to a lack of evidence. The main question our study aims to answer is:

• Is mitral regurgitant volume measured on 4D MRI more strongly related to remodeling progression (after correction of regurgitation or not) than regurgitant volume measured on 2D MRI and echocardiography?

Participants will undergo 4D MRI, 2D MRI and echocardiography twice at six-month intervals.

Detailed Description

Mitral Regurgitation (MR) is a widely prevalent valvular disease. The decision to refer patients for intervention relies on the precise quantification of MR using the mitral regurgitant volume. This quantification is primarily performed through transthoracic echocardiography (TTE), but its accuracy is limited by operator dependency and acoustic windows.

Magnetic resonance imaging (MRI) is now considered the preferred alternative technique for measuring mitral regurgitant volume using 2D phase-contrast sequences. However, it requires significant expertise from specialized centers.

4D flow MRI enables the recording of blood flow velocities in all directions across the entire cardiac volume and has demonstrated superiority over 2D MRI in other valvular diseases. However, limited data are available for validating the estimation of mitral regurgitation using 4DFlow-MRI, mainly due to the absence of a reference technique. As previously proposed for comparisons between 2D MRI and TTE, ventricular remodeling progression will be used as the evaluation criterion.

Primary Objective:

The main goal is to demonstrate that mitral regurgitant volume assessed by 4DFlow-MRI is more strongly correlated with left ventricular (LV) remodeling progression after correction or persistence of MR than mitral regurgitant volume assessed by 2D MRI or TTE, after adjustment for residual MR.

The primary outcome criterion will be the analysis of the association between the absolute change in LV end-diastolic volume (LVEDV) between baseline (M0) and 6 months after (M6) and mitral regurgitant volume at M0, as calculated by the different methods or MR severity estimated using the integrative TTE approach, adjusted for residual MR.

Secondary Objectives:

1. Evaluate the association between LV remodeling and mitral regurgitant volume measured by the different methods in the subgroup of patients undergoing percutaneous intervention, where correction is incomplete and residual MR assessment is challenging.
2. Evaluate the association between LV remodeling and mitral regurgitant volume measured by the different methods in the subgroup of patients undergoing surgical intervention, where correction is expected to be excellent with no residual MR.
3. Analyze the determinants of LV remodeling progression using novel volumetric echocardiography methods, including specific ultrafast ultrasound sequences, allowing comparisons with data from the most innovative echocardiographic techniques.
4. Investigate all determinants of LV remodeling progression at six months beyond mitral regurgitant volume, including the significance of LV remodeling, longitudinal strains of the LV and left atrium (assessed by MRI and TTE), and myocardial fibrosis derived from myocardial T1 mapping before and after gadolinium injection at M0.

Secondary Outcomes Criteria:

1. Primary evaluation criterion assessed in the subgroup of patients who underwent percutaneous MR correction.
2. Primary evaluation criterion assessed in the subgroup of patients who underwent surgical MR correction, disregarding residual MR.
3. Primary evaluation criterion assessed using innovative echographic techniques, including specific ultrafast ultrasound sequences, and compared with the standard TTE, 2D MRI and 4D MRI.
4. Changes in LV remodeling between M0 and M6, based on various indices (LVEDV, fibrosis indices, strain at M0).

• Mitral Regurgitation (MR)

• Standard echocardiography
• 2D phase-contrast magnetic resonance imaging
• 4D flow magnetic resonance imaging
• Cardiac ultrafast ultrasound imaging

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria: Subjects

• from 18 to 85 years old
• having signed a consent form to participate in the study
• suffering from mild, moderate or severe mitral regurgitation based on an ultrasound graduation
• able to undergo echocardiography and IRM within 7 days after recruitment and then at 6 months

Exclusion Criteria: Subjects

• suffering from aortic regurgitation or stenosis or mitral stenosis associated with more than moderate MR, intracardiac shunting or hypertrophic cardiomyopathy
• suffering from secondary MR
• having a contraindication to gadolinium-based contrast agent
• having a pacemaker, defibrillator or any other contraindication to MRI
• suffering from renal disease with an eGFR CKD-EPI < 30 ml/min
• pregnant or breastfeeding
• under legal protection

Enrolled subjects:

• with an incomplete or suboptimal ultrasound or MRI examination
• who have not attended to the 6-month follow-up visit
• with an intercurrent medical event

will be excluded.

Primary Purpose

Diagnostic

Allocation

Non-Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Assistance Publique - Hôpitaux de ParisOTHER

Collaborators

Ministry of Health, FranceOTHER_GOV

GIRCI IDFUNKNOWN

ariel.cohen@aphp.fr

gilles.soulat@aphp.fr